Direct-acting antiviral

This page covers all Direct-acting antiviral drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting HCV NS5B polymerase, HCV NS5A protein, Viral enzymes or proteins, Viral enzymes.

Targets

HCV NS5B polymerase, HCV NS5A protein · Viral enzymes or proteins · Viral enzymes · HCV NS5A, HCV NS3/4A protease

Phase 3 pipeline (1)

• Sofosbuvir/Ledipasvir plus Ribavirin 12W · Iran Hepatitis Network · Infectious Diseases
  Sofosbuvir/Ledipasvir plus Ribavirin works by inhibiting the HCV NS5B polymerase and NS5A protein, and also inhibiting the HCV RNA-dependent RNA polymerase, leading to the suppression of viral replication.

Phase 2 pipeline (3)

• Direct-acting antiviral agents · Qing XIe · Infectious Disease
  Direct-acting antiviral agents target viral replication by inhibiting viral enzymes or proteins.
• Direct-acting antiviral therapy · Hospices Civils de Lyon · Infectious Disease
  Direct-acting antiviral therapy targets viral replication by inhibiting viral enzymes.
• Daclatasvir and Asunaprevir · Sang Gyune Kim · Infectious Disease
  Daclatasvir and Asunaprevir are direct-acting antivirals that inhibit the HCV NS5A and NS3/4A proteases, respectively.